Should Malaria Treatment Be Guided by a Point of Care Rapid Test? A Threshold Approach to Malaria Management in Rural Burkina Faso

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Bisoffi, Zeno ^a   Tinto, Halidou ^b   Sirima, Bienvenu Sodiomon ^c   Gobbi, Federico ^a   Angheben, Andrea ^a   Buonfrate, Dora ^a   van den Ende, Jef ^d  

^a S Cuore Hospital   (Italy)

^b CENTRE MURAZ   (Burkina Faso)

^c MINISTÈRE DE LA SANTÉ   (Burkina Faso)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; ARTICLE; BURKINA FASO; CHILD; CONTROLLED STUDY; FEVER; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALARIA; POINT OF CARE TESTING; PRESCHOOL CHILD; PROBABILITY; RISK ASSESSMENT; RURAL AREA; SEASONAL VARIATION; DECISION MAKING; DRUG COMBINATION; HOSPITAL INFORMATION SYSTEM; RURAL HEALTH CARE; RURAL POPULATION; SEASON;

AMODIAQUINE; ANTIMALARIAL AGENT; DRUG COMBINATION; FANASIL, PYRIMETHAMINE DRUG COMBINATION; PYRIMETHAMINE; SULFADOXINE;

ADULT; AMODIAQUINE; ANTIMALARIALS; BURKINA FASO; CHILD, PRESCHOOL; DECISION MAKING; DRUG COMBINATIONS; FEVER; HUMANS; MALARIA; POINT-OF-CARE SYSTEMS; PROBABILITY; PYRIMETHAMINE; RURAL HEALTH SERVICES; RURAL POPULATION; SEASONS; SULFADOXINE;

EID: 84874583165     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058019     Document Type: Article

References (59)

1. WHO (2010) Guidelines for the treatment of malaria. Available: http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html. Accessed 2013 Jan 30.
2. Lubell Y, Reyburn H, Mbakilwa H, Mwangi R, Chonya S, et al. (2008) The impact of response to the results of diagnostic tests for malaria: cost-benefit analysis. BMJ 336: 202-205.
3. Bisoffi Z, Sirima SB, Menten J, Pattaro C, Angheben A, et al. (2010) Accuracy of a rapid diagnostic test on the diagnosis of malaria infection and of malaria-attributable fever during low and high transmission season in Burkina Faso. Malar J 9: 192.
4. Basinga P, Moreira J, Bisoffi Z, Bisig B, Van den Ende J, (2007) Why are clinicians reluctant to treat smear-negative tuberculosis? An inquiry about treatment thresholds in Rwanda. Med Decis Making 27: 53-60.
5. Moreira J, Alarcon F, Bisoffi Z, Rivera J, Salinas R, et al. (2008) Tuberculous meningitis: does lowering the treatment threshold result in many more treated patients? Trop Med Int Health 13: 68-75.
6. Pauker SG, Kassirer JP, (1975) Therapeutic decision making: a cost-benefit analysis. N Engl J Med 293: 229-234.
7. Nease RF Jr, Owens DK, Sox HC Jr, (1989) Threshold analysis using diagnostic tests with multiple results. Med Decis Making 9: 91-103.
8. Moons KG, Stijnen T, Michel BC, Buller HR, Van Es GA, et al. (1997) Application of treatment thresholds to diagnostic-test evaluation: an alternative to the comparison of areas under receiver operating characteristic curves. Med Decis Making 17: 447-454.
9. Richards RJ (1997) Using threshold analysis to improve medical decisions. Hosp Pract (Minneap) 32: 15-16, 19-21, 25-16.
10. McAlister FA, Laupacis A, (1998) Towards a better yardstick: the choice of treatment thresholds in hypertension. Can J Cardiol 14: 47-51.
11. Cucherat M, Boissel JP, (1998) A mathematical model for the determination of the optimum value of the treatment threshold for a continuous risk factor. Eur J Epidemiol 14: 23-29.
12. Bailey RH, Aron DC, (2000) The diagnostic dilemma of incidentalomas. Working through uncertainty. Endocrinol Metab Clin North Am 29: 91-105.
13. The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care (2000) Intracranial pressure treatment threshold. J Neurotrauma 17: 493-495.
14. McAlister FA, O'Connor AM, Wells G, Grover SA, Laupacis A, (2000) When should hypertension be treated? The different perspectives of Canadian family physicians and patients. CMAJ 163: 403-408.
15. Demyttenaere S, Finley GA, Johnston CC, McGrath PJ, (2001) Pain treatment thresholds in children after major surgery. Clin J Pain 17: 173-177.
16. Karkos CD, Vimalachandran D, Lavelle JM, Wilson P, Abraham JS, (2003) Endovascular abdominal aortic aneurysm repair outside a tertiary referral centre: feasibility and impact upon workload. Cardiovasc Surg 11: 6-11.
17. Bent S, Saint S, (2003) The optimal use of diagnostic testing in women with acute uncomplicated cystitis. Dis Mon 49: 83-98.
18. Brown JB, Nichols GA, Perry A, (2004) The burden of treatment failure in type 2 diabetes. Diabetes Care 27: 1535-1540.
19. Swain GR, McDonald RA, Pfister JR, Gradus MS, Sedmak GV, et al. (2004) Decision analysis: point-of-care Chlamydia testing vs. laboratory-based methods. Clin Med Res 2: 29-35.
20. Eltoum IA, Chen VK, Chhieng DC, Jhala D, Jhala NC, et al. (2006) Probabilistic reporting of EUS-FNA cytology: Toward improved communication and better clinical decisions. Cancer 108: 93-101.
21. Stevens TP, Harrington EW, Blennow M, Soll RF (2007) Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev: CD003063.
22. van Dijk MR, Steyerberg EW, Habbema JD, (2008) A decision-analytic approach to define poor prognosis patients: a case study for non-seminomatous germ cell cancer patients. BMC Med Inform Decis Mak 8: 1.
23. LeCroy CJ, Passman MA, Taylor SM, Patterson MA, Combs BR, et al. (2008) Should endovascular repair be used for small abdominal aortic aneurysms? Vasc Endovascular Surg 42: 113-119; discussion 120-111.
24. Anoop P, (2009) Variations in the treatment threshold for immune thrombocytopenic purpura. Pediatr Blood Cancer 52: 429.
25. Okura M, Aikawa T, Sawai NY, Iida S, Kogo M, (2009) Decision analysis and treatment threshold in a management for the N0 neck of the oral cavity carcinoma. Oral Oncol 45: 908-911.
26. Cooney MT, Dudina AL, Graham IM, (2009) Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol 54: 1209-1227.
27. Van den Ende J, Mugabekazi J, Moreira J, Seryange E, Basinga P, et al. (2010) Effect of applying a treatment threshold in a population. An example of pulmonary tuberculosis in Rwanda. J Eval Clin Pract 16: 499-508.
28. Capodanno D, Miano M, Cincotta G, Caggegi A, Ruperto C, et al. (2010) EuroSCORE refines the predictive ability of SYNTAX score in patients undergoing left main percutaneous coronary intervention. Am Heart J 159: 103-109.
29. Boland MV, Lehmann HP, (2010) A new method for determining physician decision thresholds using empiric, uncertain recommendations. BMC Med Inform Decis Mak 10: 20.
30. Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR, (2010) Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol 183: 2200-2205.
31. Martin NK, Vickerman P, Hickman M, (2011) Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 274: 58-66.
32. Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, Hess K, et al. (2011) Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol 22: 2387-2393.
33. Buclin T, Telenti A, Perera R, Csajka C, Furrer H, et al. (2011) Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy. PLoS One 6: e18578.
34. Carpenter CR, Schuur JD, Everett WW, Pines JM, (2011) Evidence-based diagnostics: adult septic arthritis. Acad Emerg Med 18: 781-796.
35. Ost DE, Gould MK, (2012) Decision making in patients with pulmonary nodules. Am J Respir Crit Care Med 185: 363-372.
36. Karthikesalingam A, Thrumurthy SG, Jackson D, Phd EC, Sayers RD, et al. (2012) Current Evidence Is Insufficient to Define an Optimal Threshold for Intervention in Isolated Type II Endoleak After Endovascular Aneurysm Repair. J Endovasc Ther 19: 200-208.
37. Kopelman RI, Wong JB, Pauker SG, (1999) Clinical problem-solving. A little math helps the medicine go down. N Engl J Med 341: 435-439.
38. Pauker SG, Kassirer JP, (1980) The threshold approach to clinical decision making. N Engl J Med 302: 1109-1117.
39. Van den Ende J, Bisoffi Z, Van Puymbroek H, Van der Stuyft P, Van Gompel A, et al. (2007) Bridging the gap between clinical practice and diagnostic clinical epidemiology: pilot experiences with a didactic model based on a logarithmic scale. J Eval Clin Pract 13: 374-380.
40. Bisoffi Z, Sirima SB, Meheus F, Lodesani C, Gobbi F, et al. (2011) Strict adherence to malaria rapid test results might lead to a neglect of other dangerous diseases: a cost benefit analysis from Burkina Faso. Malar J 10: 226.
41. Sinclair D, Gogtay N, Brand F, Olliaro P (2011) Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev: CD008492.
42. Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, et al. (2007) Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 369: 491-498.
43. Schellenberg D, Kahigwa E, Drakeley C, Malende A, Wigayi J, et al. (2002) The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 67: 17-23.
44. Obonyo CO, Juma EA, Ogutu BR, Vulule JM, Lau J, (2007) Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis. Trans R Soc Trop Med Hyg 101: 117-126.
45. Orton LC, Omari AA (2008) Drugs for treating uncomplicated malaria in pregnant women. Cochrane Database Syst Rev: CD004912.
46. de Sousa A, Rabarijaona LP, Tenkorang O, Inkoom E, Ravelomanantena HV, et al. (2012) Pharmacovigilance of malaria intermittent preventive treatment in infants coupled with routine immunizations in 6 African countries. J Infect Dis 205 (Suppl 1): S82-90.
47. Peters PJ, Thigpen MC, Parise ME, Newman RD, (2007) Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf 30: 481-501.
48. WHO (2011) International Drug Price Indicator Guide.
49. Graz B, Willcox M, Szeless T, Rougemont A, (2011) "Test and treat" or presumptive treatment for malaria in high transmission situations? A reflection on the latest WHO guidelines. Malar J 10: 136.
50. Bualombai P, Prajakwong S, Aussawatheerakul N, Congpoung K, Sudathip S, et al. (2003) Determining cost-effectiveness and cost component of three malaria diagnostic models being used in remote non-microscope areas. Southeast Asian J Trop Med Public Health 34: 322-333.
51. Rolland E, Checchi F, Pinoges L, Balkan S, Guthmann JP, et al. (2006) Operational response to malaria epidemics: are rapid diagnostic tests cost-effective? Trop Med Int Health 11: 398-408.
52. Shillcutt S, Morel C, Goodman C, Coleman P, Bell D, et al. (2008) Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull World Health Organ 86: 101-110.
53. Yukich J, D'Acremont V, Kahama J, Swai N, Lengeler C, (2010) Cost savings with rapid diagnostic tests for malaria in low-transmission areas: evidence from Dar es Salaam, Tanzania. Am J Trop Med Hyg 83: 61-68.
54. Chanda P, Castillo-Riquelme M, Masiye F, (2009) Cost-effectiveness analysis of the available strategies for diagnosing malaria in outpatient clinics in Zambia. Cost Eff Resour Alloc 7: 5.
55. Uzochukwu BS, Obikeze EN, Onwujekwe OE, Onoka CA, Griffiths UK, (2009) Cost-effectiveness analysis of rapid diagnostic test, microscopy and syndromic approach in the diagnosis of malaria in Nigeria: implications for scaling-up deployment of ACT. Malar J 8: 265.
56. Mosha JF, Conteh L, Tediosi F, Gesase S, Bruce J, et al. (2010) Cost implications of improving malaria diagnosis: findings from north-eastern Tanzania. PLoS One 5: e8707.
57. Zurovac D, Njogu J, Akhwale W, Hamer DH, Larson BA, et al. (2008) Effects of revised diagnostic recommendations on malaria treatment practices across age groups in Kenya. Trop Med Int Health 13: 784-787.
58. English M, Reyburn H, Goodman C, Snow RW, (2009) Abandoning presumptive antimalarial treatment for febrile children aged less than five years-a case of running before we can walk? PLoS Med 6: e1000015.
59. Malaria, artemisinin resistance- East Africa. ProMED-mail website. Available: http://www.promedmail.org. Accessed 2012 May 14.